X
CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19). Learn More

Docetaxel (Taxotere®)

Common name: Docetaxel
Brand name: Taxotere®
 

What is Docetaxel?

Docetaxel is a chemotherapy drug used in combination with a corticosteroid (such as prednisone or prednisolone) to treat androgen-independent metastatic prostate cancer.


How is Docetaxel administered?

Docetaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received docetaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Anemia
  • Bruising / bleeding
  • Changes to taste
  • Diarrhea
  • Fatigue
  • Fluid retention
  • Hair loss
  • Infection
  • Increase in production of tears
  • Loss of appetite
  • Mouth sores
  • Nausea / vomiting
  • Numbness, burning, tingling in hands and feet
  • Pain in joints
  • Rash

Is Docetaxel covered in my province or territory?

Docetaxel is covered by provincial drug programs in:
 
•    Alberta
•    British Columbia
•    Nova Scotia
•    Ontario
•    Quebec
•    Saskatchewan
•    Yukon
 
Docetaxel is not covered by provincial drug programs in:
 
•    New Brunswick
•    Newfoundland & Labrador
•    Prince Edward Island
•    Nunavut
•    Northwest Territories

Unknown if docetaxel is covered by provincial drug programs in:
•    Manitoba



 
    Last Reviewed: July 2017
Prostate Cancer Canada and Canadian Cancer Society








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.
More

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More


Click here for news archive